Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder

Abstract

Gly/gly DRD-3 genotype predicted statistically and clinically significantly better acute positive symptom reduction compared with other ser-9-gly genotypes in patients treated with olanzapine.

Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs

“…This is in line with an initial metaanalysis showing better outcome to clozapine treatment in Gly-carriers, but these results were only partially confirmed in a recent and larger multi-ethnic metanalysis (Hwang et al, 2010). In another study Gly-carries with schizophrenia were also found more responsive to olanzepine in a controlled clinical trial, showing greater positive symptom remission in 39% of subjects with Gly/Gly and Gly/Ser genotypes vs. 14% subjects with Ser/Ser genotype (Adams et al, 2008). However, negative studies can be also found in the literature.…”

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia

“…In all, 22 SNPs were selected on the basis of prior knowledge of their involvement with response to risperidone or to other antipsychotic drugs. The selected SNPs and genes included ANKK1 (rs1800497 [4][5][6][7][8][9][10][11][12][13][14][15][16][17] Genotyping was performed by Cogenics (Newton, MA, USA) using Sequenom MassARRAY iPlex as previously described. 20 Statistical analysis African-American and white patients who had received at least one dose of risperidone between week 0 and study end (week 12) and who had consented to DNA testing were included in the analysis.…”

“…In the current study, we present results from an analysis of the association between antipsychotic response and 22 single-nucleotide polymorphisms (SNPs), earlier reported to be associated with antipsychotic response, [4][5][6][7][8][9][10][11][12][13][14][15][16][17] using data from a randomized, double-blind study of early response to a single drug (risperidone) in patients with schizophrenia, schizoaffective disorder or schizophreniform disorder. 18 The majority of patients in the trial were African-American and white adults, the former being a group that has been underrepresented in pharmacogenomic studies.…”

Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics

“…Three studies have reported association of DRD3 Ser9Gly genotype with general improvement in psychotic symptoms following treatment with first-and secondgeneration antipsychotics [42][43][44], while three other studies have reported association with specific improvement in positive symptomatology [45][46][47] (OR= 1.4-4.7) [26]. In vitro studies indicate higher dopamine binding affinity in the Gly variant.…”